Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified August 2011
Feeds
4628 items (4628 unread) in 80 feeds
Acinar Cell Carcinoma
(29 unread)
Acinic Cell Carcinoma
(33 unread)
Adenoid Cystic Carcinoma
(57 unread)
Adrenal Gland Cancer
(335 unread)
Ampulla Of Vater
(14 unread)
Anal Cancer
(252 unread)
Angiosarcoma
(73 unread)
Appendix Cancer
(35 unread)
Bile Duct Cancer
(386 unread)
Brain and CNS
(1151 unread)
Carcinoid
(143 unread)
Endocrine/Neuroendocrine
(291 unread)
Gall Bladder Cancer
(227 unread)
Hemangioendothelioma
(23 unread)
Hepatoblastoma
(31 unread)
Pancreas
(45 unread)
Phyllodes
(21 unread)
PMP and Mucinous Tumors
(19 unread)
Rhabdomyosarcoma
(191 unread)
Sarcoma
(602 unread)
Twitter Pals
(670 unread)
Trial - Brain Tumor (2 unread)
-
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Posted: June 27th, 2009, 8:00am MDT
-
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Posted: June 5th, 2009, 8:00am MDT
Condition: Central Nervous System Lymphoma
Intervention: Drug: pemetrexed
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Eli Lilly and Company; Dana-Farber Cancer Institute
Recruiting - verified April 2012